Busulphan

Pediatric Cancer

Malika KapadiaPhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

32 Active assets in the Pediatric Cancer cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB
Nivolumab Australian & New Zealand Children's Haematology/Oncology Group	Phase 2	B
Ifosfamide Samsung Medical Center	Phase 2	B
OTL-38 Mayo Clinic	Phase 3	B

View all 50 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant

BBB

Indicative ·

77 / 100

myelodysplastic/myeloproliferative neoplasmDormant

BBB

Indicative ·

76 / 100

graft versus host diseaseDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.